Aurora Kinase A (Aurora 2 or EC 2.7.11.1) Market Size, Definition, Treatment, Causes, Pipeline Review, H1 2016
Global Markets Direct's, 'Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) - Pipeline Review, H1 2016', provides in depth analysis on Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) targeted pipeline therapeutics. Read More @ http://www.radiantinsights.com/research/aurora-kinase-a-serine-threonine-protein-kinase
Global Markets Direct's, 'Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) - Pipeline Review, H1 2016', provides in depth analysis on Aurora Kinase A (Serine/Threonine-Protein Kinase 15 or Aurora/IPL1-Related Kinase 1 or Aurora 2 or EC 2.7.11.1) targeted pipeline therapeutics.
Read More @ http://www.radiantinsights.com/research/aurora-kinase-a-serine-threonine-protein-kinase
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Aur<strong>or</strong>a</strong> <strong>Kinase</strong> A (<strong>Aur<strong>or</strong>a</strong> 2 <strong>or</strong> <strong>EC</strong> <strong>2.7.11.1</strong>) <strong>Market</strong> Share, <strong>Size</strong>,<br />
<strong>Definition</strong>, Symptoms, <strong>Pipeline</strong> <strong>Review</strong>, <strong>H1</strong> <strong>2016</strong>: Radiant<br />
Insights<br />
Summary<br />
Global <strong>Market</strong>s Direct's, '<strong>Aur<strong>or</strong>a</strong> <strong>Kinase</strong> A (Serine/Threonine-Protein <strong>Kinase</strong> 15 <strong>or</strong> <strong>Aur<strong>or</strong>a</strong>/IPL1-Related <strong>Kinase</strong> 1 <strong>or</strong><br />
<strong>Aur<strong>or</strong>a</strong> 2 <strong>or</strong> <strong>EC</strong> <strong>2.7.11.1</strong>) - <strong>Pipeline</strong> <strong>Review</strong>, <strong>H1</strong> <strong>2016</strong>', provides in depth analysis on <strong>Aur<strong>or</strong>a</strong> <strong>Kinase</strong> A<br />
(Serine/Threonine-Protein <strong>Kinase</strong> 15 <strong>or</strong> <strong>Aur<strong>or</strong>a</strong>/IPL1-Related <strong>Kinase</strong> 1 <strong>or</strong> <strong>Aur<strong>or</strong>a</strong> 2 <strong>or</strong> <strong>EC</strong> <strong>2.7.11.1</strong>) targeted pipeline<br />
therapeutics.<br />
The rep<strong>or</strong>t provides comprehensive inf<strong>or</strong>mation on the <strong>Aur<strong>or</strong>a</strong> <strong>Kinase</strong> A (Serine/Threonine-Protein <strong>Kinase</strong> 15 <strong>or</strong><br />
<strong>Aur<strong>or</strong>a</strong>/IPL1-Related <strong>Kinase</strong> 1 <strong>or</strong> <strong>Aur<strong>or</strong>a</strong> 2 <strong>or</strong> <strong>EC</strong> <strong>2.7.11.1</strong>), targeted therapeutics, complete with analysis by<br />
indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.<br />
The rep<strong>or</strong>t also covers the descriptive pharmacological action of the therapeutics, its complete research and<br />
development hist<strong>or</strong>y and latest news and press releases. Additionally, the rep<strong>or</strong>t provides an overview of key<br />
players involved in <strong>Aur<strong>or</strong>a</strong> <strong>Kinase</strong> A (Serine/Threonine-Protein <strong>Kinase</strong> 15 <strong>or</strong> <strong>Aur<strong>or</strong>a</strong>/IPL1-Related <strong>Kinase</strong> 1 <strong>or</strong> <strong>Aur<strong>or</strong>a</strong><br />
2 <strong>or</strong> <strong>EC</strong> <strong>2.7.11.1</strong>) targeted therapeutics development and features d<strong>or</strong>mant and discontinued projects.<br />
Browse Ongoing Rep<strong>or</strong>ts @ http://www.radiantinsights.com/research/aur<strong>or</strong>a-kinase-a-serine-threonineprotein-kinase<br />
Global <strong>Market</strong>s Direct's rep<strong>or</strong>t features investigational drugs from across globe covering over 20 therapy areas and<br />
nearly 3,000 indications. The rep<strong>or</strong>t is built using data and inf<strong>or</strong>mation sourced from Global <strong>Market</strong>s Direct's<br />
proprietary databases, company/university websites, clinical trial registries, conferences, S<strong>EC</strong> filings, invest<strong>or</strong><br />
presentations and featured press releases from company/university sites and industry-specific third party sources.<br />
Drug profiles featured in the rep<strong>or</strong>t undergoes periodic review following a stringent set of processes to ensure that<br />
all the profiles are updated with the latest set of inf<strong>or</strong>mation. Additionally, various dynamic tracking processes<br />
ensure that the most recent developments are captured on a real time basis.<br />
The rep<strong>or</strong>t helps in identifying and tracking emerging players in the market and their p<strong>or</strong>tfolios, enhances decision<br />
making capabilities and helps to create effective counter strategies to gain competitive advantage.<br />
Note*: Certain sections in the rep<strong>or</strong>t may be removed <strong>or</strong> altered based on the availability and relevance of data.<br />
Scope<br />
- The rep<strong>or</strong>t provides a snapshot of the global therapeutic landscape f<strong>or</strong> <strong>Aur<strong>or</strong>a</strong> <strong>Kinase</strong> A (Serine/Threonine-<br />
Protein <strong>Kinase</strong> 15 <strong>or</strong> <strong>Aur<strong>or</strong>a</strong>/IPL1-Related <strong>Kinase</strong> 1 <strong>or</strong> <strong>Aur<strong>or</strong>a</strong> 2 <strong>or</strong> <strong>EC</strong> <strong>2.7.11.1</strong>)
- The rep<strong>or</strong>t reviews <strong>Aur<strong>or</strong>a</strong> <strong>Kinase</strong> A (Serine/Threonine-Protein <strong>Kinase</strong> 15 <strong>or</strong> <strong>Aur<strong>or</strong>a</strong>/IPL1-Related <strong>Kinase</strong> 1 <strong>or</strong><br />
<strong>Aur<strong>or</strong>a</strong> 2 <strong>or</strong> <strong>EC</strong> <strong>2.7.11.1</strong>) targeted therapeutics under development by companies and universities/research<br />
institutes based on inf<strong>or</strong>mation derived from company and industry-specific sources<br />
- The rep<strong>or</strong>t covers pipeline products based on various stages of development ranging from pre-registration till<br />
discovery and undisclosed stages<br />
- The rep<strong>or</strong>t features descriptive drug profiles f<strong>or</strong> the pipeline products which includes, product description,<br />
descriptive MoA, R&D brief, licensing and collab<strong>or</strong>ation details & other developmental activities<br />
- The rep<strong>or</strong>t reviews key players involved in <strong>Aur<strong>or</strong>a</strong> <strong>Kinase</strong> A (Serine/Threonine-Protein <strong>Kinase</strong> 15 <strong>or</strong> <strong>Aur<strong>or</strong>a</strong>/IPL1-<br />
Related <strong>Kinase</strong> 1 <strong>or</strong> <strong>Aur<strong>or</strong>a</strong> 2 <strong>or</strong> <strong>EC</strong> <strong>2.7.11.1</strong>) targeted therapeutics and enlists all their maj<strong>or</strong> and min<strong>or</strong> projects<br />
- The rep<strong>or</strong>t assesses <strong>Aur<strong>or</strong>a</strong> <strong>Kinase</strong> A (Serine/Threonine-Protein <strong>Kinase</strong> 15 <strong>or</strong> <strong>Aur<strong>or</strong>a</strong>/IPL1-Related <strong>Kinase</strong> 1 <strong>or</strong><br />
<strong>Aur<strong>or</strong>a</strong> 2 <strong>or</strong> <strong>EC</strong> <strong>2.7.11.1</strong>) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA)<br />
and molecule type<br />
- The rep<strong>or</strong>t summarizes all the d<strong>or</strong>mant and discontinued pipeline projects<br />
- The rep<strong>or</strong>t reviews latest news and deals related to <strong>Aur<strong>or</strong>a</strong> <strong>Kinase</strong> A (Serine/Threonine-Protein <strong>Kinase</strong> 15 <strong>or</strong><br />
<strong>Aur<strong>or</strong>a</strong>/IPL1-Related <strong>Kinase</strong> 1 <strong>or</strong> <strong>Aur<strong>or</strong>a</strong> 2 <strong>or</strong> <strong>EC</strong> <strong>2.7.11.1</strong>) targeted therapeutics<br />
Buy a Sample Copy of This Rep<strong>or</strong>t @ http://www.radiantinsights.com/research/aur<strong>or</strong>a-kinase-a-serinethreonine-protein-kinase/request-sample<br />
Table of Contents<br />
Table of Contents 2<br />
List of Tables 5<br />
List of Figures 6<br />
Introduction 7<br />
Global <strong>Market</strong>s Direct Rep<strong>or</strong>t Coverage 7<br />
<strong>Aur<strong>or</strong>a</strong> <strong>Kinase</strong> A (Serine/Threonine-Protein <strong>Kinase</strong> 15 <strong>or</strong> <strong>Aur<strong>or</strong>a</strong>/IPL1-Related <strong>Kinase</strong> 1 <strong>or</strong> <strong>Aur<strong>or</strong>a</strong> 2 <strong>or</strong> <strong>EC</strong> <strong>2.7.11.1</strong>)<br />
Overview 8<br />
Therapeutics Development 9<br />
<strong>Aur<strong>or</strong>a</strong> <strong>Kinase</strong> A (Serine/Threonine-Protein <strong>Kinase</strong> 15 <strong>or</strong> <strong>Aur<strong>or</strong>a</strong>/IPL1-Related <strong>Kinase</strong> 1 <strong>or</strong> <strong>Aur<strong>or</strong>a</strong> 2 <strong>or</strong> <strong>EC</strong> <strong>2.7.11.1</strong>) -<br />
Products under Development by Stage of Development 9<br />
<strong>Aur<strong>or</strong>a</strong> <strong>Kinase</strong> A (Serine/Threonine-Protein <strong>Kinase</strong> 15 <strong>or</strong> <strong>Aur<strong>or</strong>a</strong>/IPL1-Related <strong>Kinase</strong> 1 <strong>or</strong> <strong>Aur<strong>or</strong>a</strong> 2 <strong>or</strong> <strong>EC</strong> <strong>2.7.11.1</strong>) -<br />
Products under Development by Therapy Area 10<br />
<strong>Aur<strong>or</strong>a</strong> <strong>Kinase</strong> A (Serine/Threonine-Protein <strong>Kinase</strong> 15 <strong>or</strong> <strong>Aur<strong>or</strong>a</strong>/IPL1-Related <strong>Kinase</strong> 1 <strong>or</strong> <strong>Aur<strong>or</strong>a</strong> 2 <strong>or</strong> <strong>EC</strong> <strong>2.7.11.1</strong>) -<br />
Products under Development by Indication 11<br />
<strong>Aur<strong>or</strong>a</strong> <strong>Kinase</strong> A (Serine/Threonine-Protein <strong>Kinase</strong> 15 <strong>or</strong> <strong>Aur<strong>or</strong>a</strong>/IPL1-Related <strong>Kinase</strong> 1 <strong>or</strong> <strong>Aur<strong>or</strong>a</strong> 2 <strong>or</strong> <strong>EC</strong> <strong>2.7.11.1</strong>) -<br />
<strong>Pipeline</strong> Products Glance 13<br />
Late Stage Products 13<br />
Early Stage Products 14<br />
<strong>Aur<strong>or</strong>a</strong> <strong>Kinase</strong> A (Serine/Threonine-Protein <strong>Kinase</strong> 15 <strong>or</strong> <strong>Aur<strong>or</strong>a</strong>/IPL1-Related <strong>Kinase</strong> 1 <strong>or</strong> <strong>Aur<strong>or</strong>a</strong> 2 <strong>or</strong> <strong>EC</strong> <strong>2.7.11.1</strong>) -<br />
Products under Development by Companies 15<br />
Browse Ongoing Rep<strong>or</strong>ts @ http://www.radiantinsights.com/research/aur<strong>or</strong>a-kinase-a-serine-threonineprotein-kinase<br />
About Us:<br />
Radiant Insights Inc. is a platf<strong>or</strong>m f<strong>or</strong> companies looking to meet their market research and business intelligence<br />
requirements. We assist and facilitate <strong>or</strong>ganizations and individuals procure market research rep<strong>or</strong>ts, helping them<br />
in the decision making process. We have a comprehensive collection of rep<strong>or</strong>ts, covering over 40 key industries<br />
and a host of micro markets. In addition to over extensive database of rep<strong>or</strong>ts, our experienced research<br />
co<strong>or</strong>dinat<strong>or</strong>s also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research<br />
solutions.<br />
Contact Details:
Michelle Th<strong>or</strong>as<br />
C<strong>or</strong>p<strong>or</strong>ate Sales Specialist, USA<br />
Radiant Insights, Inc<br />
28 2nd Street,<br />
Suite 3036 San Francisco,<br />
CA 94105 United States<br />
Phone: 1-415-349-0054<br />
Toll Free: 1-888-202-9519<br />
Website: http://www.radiantinsights.com/<br />
Email: sales@radiantinsights.com<br />
Visit our Blog: http://chemicalsandmaterialsri.blogspot.com
Change language